FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2948585504> ?p ?o ?g. }

• W2948585504 abstract "Purpose: To perform a multi-institutional analysis following treatment of limited osseous and/or nodal metastases in patients using a novel hypofractionated image-guided radiotherapy with simultaneous-integrated boost (HIGRT-SIB) technique. Methods: Consecutive patients treated with HIGRT-SIB for ≤5 active metastases at Duke University Medical Center or Durham Veterans’ Affairs Medical Center between 2013-2018 were analyzed to determine toxicities and recurrence patterns following treatment. Most patients received 50 Gy to the PTVboost and 30 Gy to the PTVelect simultaneously in 10 fractions. High-dose treatment volume recurrence (HDTVR) and low-dose treatment volume recurrence (LDTVR) were defined as recurrences within PTVboost and PTVelect, respectively. Marginal recurrence (MR) was defined as recurrence outside PTVelect, but within the adjacent bone or nodal chain. Distant recurrence (DR) was defined as recurrences not meeting HDTVR, LDTVR, or MR criteria. Freedom from pain recurrence (FFPR) was calculated in patients with painful osseous metastases prior to HIGRT-SIB. Outcome rates were estimated at 12 months using the Kaplan-Meier method. Results: 42 patients met inclusion criteria with 59 sites treated with HIGRT-SIB (53% nodal and 47% osseous). Median time from diagnosis to first metastasis was 31 months and the median age at HIGRT-SIB was 69 years. The most common primary tumors were prostate (36%), gastrointestinal (24%), and lung (24%). Median follow-up was 11 months. One acute grade ≥3 toxicity (febrile neutropenia) occurred after docetaxel administration immediately following HIGRT-SIB. Four patients developed late grade ≥3 toxicities: two ipsilateral vocal cord paralyses and two vertebral compression fractures. The overall pain response rate was 94% and the estimated FFPR at 12 months was 72%. The estimated 12-month rate of HDTVR, LDTVR, MR, and DR was 3.6%, 6.2%, 7.6%, and 55.8%, respectively. DR preceded MR, HDTVR, or LDTVR in each instance. Conclusion: Targeting areas at high-risk for occult disease with a lower radiation dose, while simultaneously boosting gross disease with HIGRT in patients with limited osseous and/or nodal metastases, has a high rate of treated metastasis control, a low rate of MR, acceptable toxicity, and high rate of pain palliation. Further investigation with prospective trials is warranted." @default.
• W2948585504 created "2019-06-14" @default.
• W2948585504 creator A5009234970 @default.
• W2948585504 creator A5019376688 @default.
• W2948585504 creator A5026440190 @default.
• W2948585504 creator A5057160239 @default.
• W2948585504 creator A5059865374 @default.
• W2948585504 creator A5066986846 @default.
• W2948585504 creator A5073542502 @default.
• W2948585504 date "2019-06-04" @default.
• W2948585504 modified "2023-09-26" @default.
• W2948585504 title "Hypofractionated Image-Guided Radiation Therapy With Simultaneous-Integrated Boost Technique for Limited Metastases: A Multi-Institutional Analysis" @default.
• W2948585504 cites W1548787353 @default.
• W2948585504 cites W1608460440 @default.
• W2948585504 cites W1963798982 @default.
• W2948585504 cites W1965531668 @default.
• W2948585504 cites W1969840990 @default.
• W2948585504 cites W1969931281 @default.
• W2948585504 cites W1984237057 @default.
• W2948585504 cites W1986920424 @default.
• W2948585504 cites W1998241538 @default.
• W2948585504 cites W1998726546 @default.
• W2948585504 cites W2009652019 @default.
• W2948585504 cites W2019582591 @default.
• W2948585504 cites W2022970651 @default.
• W2948585504 cites W2031688279 @default.
• W2948585504 cites W2038940811 @default.
• W2948585504 cites W2049021862 @default.
• W2948585504 cites W2077080208 @default.
• W2948585504 cites W2085278478 @default.
• W2948585504 cites W2094000412 @default.
• W2948585504 cites W2107890915 @default.
• W2948585504 cites W2110069491 @default.
• W2948585504 cites W2115092415 @default.
• W2948585504 cites W2123755654 @default.
• W2948585504 cites W2127240958 @default.
• W2948585504 cites W2155679250 @default.
• W2948585504 cites W2157986653 @default.
• W2948585504 cites W2158546346 @default.
• W2948585504 cites W2160196898 @default.
• W2948585504 cites W2168206838 @default.
• W2948585504 cites W2170356223 @default.
• W2948585504 cites W2264241948 @default.
• W2948585504 cites W2268596702 @default.
• W2948585504 cites W2342476337 @default.
• W2948585504 cites W2394715858 @default.
• W2948585504 cites W2519294778 @default.
• W2948585504 cites W2536769127 @default.
• W2948585504 cites W2558960775 @default.
• W2948585504 cites W2663943212 @default.
• W2948585504 cites W2761351587 @default.
• W2948585504 cites W2800033575 @default.
• W2948585504 cites W2803766273 @default.
• W2948585504 cites W2898937010 @default.
• W2948585504 cites W2939770857 @default.
• W2948585504 cites W2942040016 @default.
• W2948585504 cites W4240340450 @default.
• W2948585504 doi "https://doi.org/10.3389/fonc.2019.00469" @default.
• W2948585504 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6558188" @default.
• W2948585504 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31214509" @default.
• W2948585504 hasPublicationYear "2019" @default.
• W2948585504 type Work @default.
• W2948585504 sameAs 2948585504 @default.
• W2948585504 citedByCount "4" @default.
• W2948585504 countsByYear W29485855042021 @default.
• W2948585504 countsByYear W29485855042022 @default.
• W2948585504 countsByYear W29485855042023 @default.
• W2948585504 crossrefType "journal-article" @default.
• W2948585504 hasAuthorship W2948585504A5009234970 @default.
• W2948585504 hasAuthorship W2948585504A5019376688 @default.
• W2948585504 hasAuthorship W2948585504A5026440190 @default.
• W2948585504 hasAuthorship W2948585504A5057160239 @default.
• W2948585504 hasAuthorship W2948585504A5059865374 @default.
• W2948585504 hasAuthorship W2948585504A5066986846 @default.
• W2948585504 hasAuthorship W2948585504A5073542502 @default.
• W2948585504 hasBestOaLocation W29485855041 @default.
• W2948585504 hasConcept C126322002 @default.
• W2948585504 hasConcept C126838900 @default.
• W2948585504 hasConcept C141071460 @default.
• W2948585504 hasConcept C2776694085 @default.
• W2948585504 hasConcept C2777063308 @default.
• W2948585504 hasConcept C2777714996 @default.
• W2948585504 hasConcept C2781190966 @default.
• W2948585504 hasConcept C509974204 @default.
• W2948585504 hasConcept C71924100 @default.
• W2948585504 hasConceptScore W2948585504C126322002 @default.
• W2948585504 hasConceptScore W2948585504C126838900 @default.
• W2948585504 hasConceptScore W2948585504C141071460 @default.
• W2948585504 hasConceptScore W2948585504C2776694085 @default.
• W2948585504 hasConceptScore W2948585504C2777063308 @default.
• W2948585504 hasConceptScore W2948585504C2777714996 @default.
• W2948585504 hasConceptScore W2948585504C2781190966 @default.
• W2948585504 hasConceptScore W2948585504C509974204 @default.
• W2948585504 hasConceptScore W2948585504C71924100 @default.
• W2948585504 hasLocation W29485855041 @default.
• W2948585504 hasLocation W29485855042 @default.
• W2948585504 hasLocation W29485855043 @default.
• W2948585504 hasLocation W29485855044 @default.
• W2948585504 hasOpenAccess W2948585504 @default.
• W2948585504 hasPrimaryLocation W29485855041 @default.

• next